Isoprenaline Chlorhydrate Tillomed (Isoprenaline Hydrochloride)

Isoprenaline Hydrochloride acts as a non‑selective agonist at β1 and β2 adrenergic receptors. Stimulation of β1 receptors in cardiac tissue raises cyclic AMP, enhancing pacemaker activity and contractility. Activation of β2 receptors in bronchial smooth muscle also raises cyclic AMP, causing muscle relaxation and bronchodilation, thereby improving airflow.

The dosage of Isoprenaline Chlorhydrate Tillomed is determined by the prescribing clinician based on the patient’s clinical condition, response, and route of administration. Healthcare professionals adjust the infusion rate or injection volume to achieve the desired heart rate or bronchodilatory effect while monitoring safety parameters.

Safety data for Isoprenaline Hydrochloride in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider after careful assessment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Isoprenaline is a non‑selective β1/β2 agonist, providing both cardiac stimulation and bronchodilation, whereas agents like albuterol are selective for β2 receptors and primarily used for asthma. Compared with selective β1 agents such as dobutamine, Isoprenaline has a stronger chronotropic effect but may cause more peripheral side effects due to β2 activity.

The product should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Do not use if the solution appears discolored or contains particles.

Isoprenaline is supplied as an injectable solution for intravenous or subcutaneous administration. The route, infusion rate, or injection volume is set by the prescriber and administered by qualified medical personnel, with continuous monitoring of cardiovascular parameters during use.

Serious risks include life‑threatening arrhythmias, myocardial ischemia, severe hypertension or hypotension, pulmonary edema, and allergic reactions such as anaphylaxis. Prompt recognition and management of these events are essential, and patients should be monitored closely during therapy.

Isoprenaline is contraindicated in patients with known hypersensitivity to the drug, uncontrolled ventricular tachyarrhythmias, severe coronary artery disease, recent myocardial infarction, or those taking non‑selective beta‑blockers that cannot be discontinued. Caution is also advised in hyperthyroid patients and those with severe hypertension.